Advertisement
Advertisement

IOVA

IOVA logo

Iovance Biotherapeutics, Inc. Common Stock

6.02
USD
Sponsored
+1.68
+38.80%
Aug 06, 11:00 UTC -4
Open

Iovance Biotherapeutics, Inc. Common Stock Profile

About

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.

Info & Links

CEO

Frederick G. Vogt

Headquarters

825 INDUSTRIAL ROAD, SUITE 100
SAN CARLOS, CA 94070, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.iovance.com

Auditor

Ernst & Young LLP

Share holders

18

Employees

975

Iovance Biotherapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

2.69B

Enterprise Value

2.49B

Enterprise Value/EBITDA(ttm)

-7.71

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

6.82

Price to Book(mrq)

2.70

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

37.06%

Operating Margin(ttm)

-123.92%

Profit Margin(ttm)

-128.76%

Return on Equity(ttm)

-50.17%

Return on Invested Capital(ttm)

-50.22%

Return on Assets(ttm)

-38.77%

Income Statement

Revenue(ttm)

285.61M

Revenue Per Share(ttm)

0.64

Gross Profit(ttm)

112.64M

EBITDA(ttm)3

-323.58M

Net Income Available to Common(ttm)

-353.86M

Diluted EPS(ttm)

-0.95

Share Statistics

Beta (5Y Monthly)

0.71

52-Week Change

119.05%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

446.50M

Dividend Yield

0.00%

Float4

411.68M

% Held by Insiders

7.80%

% Held by Institutions

77.03%

Balance Sheet

Total Cash(mrq)

313.44M

Total Cash Per Share(mrq)

0.70

Total Debt(mrq)

1000.00K

Total Debt/Equity(mrq)

0.14%

Current Ratio(mrq)

3.60%

Quick Ratio(mrq)

3.15%

Book Value Per Share(mrq)

1.65

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.17

Free Cash Flow(ytd)

-78.68M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement